



3rd February 2009

Company Announcements Office
Australian Securities Exchange

TGA Approves Trophon™ EPR for Commercial Launch in Australia & Overseas

First Sales on Track for February 2009

Nanosonics Limited (ASX code: NAN) is pleased to announce that today it has received full approval and certification to market the Trophon EPR from the Australian Therapeutic Goods Administration (TGA). This certification by an internationally respected regulatory body delivers a critical milestone in the global rollout of the Trophon product. This achievement now enables the Company to recognise sales revenues from Australia and New Zealand initially and then international markets in line with the Company strategy.

SALES REVENUES

Commercial shipments into both Australia and New Zealand will commence in February with rollout into targeted European markets following in March 2009. The TGA approval now enables the Company to enter these markets and take advantage of the rapidly changing legislative requirements, which demands high level disinfection of intracavity ultrasound probes between each patient.

This growing market for high level disinfection in an easy to use and environmentally friendly system is driving strong customer demand for the product. Nanosonics is receiving an increased level of enquiries from global markets who wish to gain the earliest possible access to the novel NanoNebulant™ technology.

PRODUCT PIPELINE

The Company enjoys a strong product development pipeline leveraging the NanoNebulant technology, with the parallel development of 3 significant prototypes for which there is advanced commercial interest. The Company anticipates further release of new products later in this calendar year.

David Radford
CEO

For more information please contact David Radford, CEO, or Chris Grundy, CFO, on 61-2-8063 1600.



About Nanosonics

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets.

Initial market applications are designed for the reprocessing of reusable medical instruments. The Company's first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries.

Nanosonics has recently upgraded its website. Please visit www.nanosonics.com.au for up-to-date information about the Company.